146 related articles for article (PubMed ID: 34274223)
1. [Ultra-hypofractionated radiotherapy for the treatment of localized prostate cancer: Results, limits and prospects].
Graff P; Crehange G
Cancer Radiother; 2021 Oct; 25(6-7):684-691. PubMed ID: 34274223
[TBL] [Abstract][Full Text] [Related]
2. Prostate re-irradiation: current concerns and future perspectives.
Cuccia F; Mazzola R; Nicosia L; Giaj-Levra N; Figlia V; Ricchetti F; Rigo M; Vitale C; Corradini S; Alongi F
Expert Rev Anticancer Ther; 2020 Nov; 20(11):947-956. PubMed ID: 32909471
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body re-irradiation therapy for locally recurrent prostate cancer after external-beam radiation therapy: Initial report.
Janoray G; Reynaud-Bougnoux A; Ruffier-Loubière A; Bernadou G; Pointreau Y; Calais G
Cancer Radiother; 2016 Jun; 20(4):275-81. PubMed ID: 27342944
[TBL] [Abstract][Full Text] [Related]
4. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM
Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronic acid spacer in focal prostate reirradiation: A single centre experience.
Ozyigit G; Hurmuz P; Akinci D; Esen SCB; Yilmaz MT; Akdogan B; Akyol FH
Cancer Radiother; 2020 Dec; 24(8):805-811. PubMed ID: 32565071
[TBL] [Abstract][Full Text] [Related]
6. Salvage reirradiation for local prostate cancer recurrence after radiation therapy. For who? When? How?
Baty M; Créhange G; Pasquier D; Palard X; Deleuze A; Gnep K; Key S; Beuzit L; Castelli J; de Crevoisier R
Cancer Radiother; 2019 Oct; 23(6-7):541-558. PubMed ID: 31421999
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse.
Kinj R; Doyen J; Hannoun-Lévi JM; Naghavi AO; Chand ME; Baudin G; Ferrero JM; François E; Evesque L; Borchiellini D; Benezery K; Bondiau PY
Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):e15-e21. PubMed ID: 32641243
[TBL] [Abstract][Full Text] [Related]
8. PROLAPSE: survey about local prostate cancer relapse salvage treatment with external beam re-irradiation: results of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
Zerini D; Jereczek-Fossa BA; Ciabattoni A; Mirri A; Bertoni F; Fersino S; D'Agostino G; Lohr F; Mortellaro G; Triggiani L; Marvaso G; Pepa M; Cuccia F; Alongi F;
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2311-2317. PubMed ID: 32583236
[TBL] [Abstract][Full Text] [Related]
9. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients.
Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979
[TBL] [Abstract][Full Text] [Related]
10. Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy.
D'Agostino GR; Di Brina L; Mancosu P; Franzese C; Iftode C; Franceschini D; Clerici E; Tozzi A; Navarria P; Scorsetti M
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):614-621. PubMed ID: 30825495
[TBL] [Abstract][Full Text] [Related]
11. Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer.
Cuccia F; Nicosia L; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Vitale C; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Jul; 196(7):628-636. PubMed ID: 32399638
[TBL] [Abstract][Full Text] [Related]
12. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
[TBL] [Abstract][Full Text] [Related]
13. Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer.
Bergamin S; Eade T; Kneebone A; Booth J; Hsiao E; Schembri GP; Szymura K; Le A; Kwong C; Brown C; Hunter J; Hruby G
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1172-1178. PubMed ID: 32659332
[TBL] [Abstract][Full Text] [Related]
14. Early Results of Extreme Hypofractionation Using Stereotactic Body Radiation Therapy for High-risk, Very High-risk and Node-positive Prostate Cancer.
Murthy V; Gupta M; Mulye G; Maulik S; Munshi M; Krishnatry R; Phurailatpam R; Mhatre R; Prakash G; Bakshi G
Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):442-447. PubMed ID: 29571936
[TBL] [Abstract][Full Text] [Related]
15. Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT).
Jereczek-Fossa BA; Rojas DP; Zerini D; Fodor C; Viola A; Fanetti G; Volpe S; Luraschi R; Bazani A; Rondi E; Cattani F; Vavassori A; Garibaldi C; Alessi S; Pricolo P; Petralia G; Cozzi G; De Cobelli O; Musi G; Orecchia R; Marvaso G; Ciardo D
Br J Radiol; 2019 Feb; 92(1094):20180494. PubMed ID: 30379566
[TBL] [Abstract][Full Text] [Related]
16. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
[TBL] [Abstract][Full Text] [Related]
17. A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
Kole TP; Nichols RC; Lei S; Wu B; Huh SN; Morris CG; Lee S; Tong M; Mendenhall NP; Dritschilo A; Collins SP
Acta Oncol; 2015 Jun; 54(6):825-31. PubMed ID: 25227898
[TBL] [Abstract][Full Text] [Related]
18. [Moderate or extreme hypofractionation and localized prostate cancer: The times are changing].
Line Krhili S; Créhange G; Albert-Dufrois H; Guimas V; Minsat M; Supiot S
Cancer Radiother; 2019 Oct; 23(6-7):503-509. PubMed ID: 31471253
[TBL] [Abstract][Full Text] [Related]
19. SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.
Rucinska M; Kieszkowska-Grudny A; Nawrocki S
Strahlenther Onkol; 2016 Jul; 192(7):449-57. PubMed ID: 27221312
[TBL] [Abstract][Full Text] [Related]
20. A Multicenter Phase 2 study of Hypofractionated Stereostatic Boost in Intermediate Risk Prostate Carcinoma: A 5-Year Analysis of the CKNO-PRO Trial.
Pasquier D; Peiffert D; Nickers P; Maingon P; Pommier P; Lacornerie T; Martinage G; Tresch E; Lartigau E
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):116-123. PubMed ID: 31604131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
